-
公开(公告)号：US20240132479A1
公开(公告)日：2024-04-25
申请号：US18274705
申请日：2022-01-28
IPC分类号： C07D403/06 , A61P31/04 , C07D235/16 , C07D235/26 , C07D235/28 , C07D401/04 , C07D401/06 , C07D401/12 , C07D403/04
CPC分类号： C07D403/06 , A61P31/04 , C07D235/16 , C07D235/26 , C07D235/28 , C07D401/04 , C07D401/06 , C07D401/12 , C07D403/04
摘要： A liner in a label-liner combination is provided with a die cut portion made in the liner. The die cut portion is aligned with at least one edge in a label and a front side of the liner is attached to a backside of the label. The die cut portion of the liner is adapted to be removed from the liner when the label is removed from the label-liner combination. Dimensions, and orientation, and a location of the die cut portion in the liner are adapted to allow the label to be removed from the label-liner combination and applied to a surface by digits of a hand without touching an adhesive coating on the backside of the label and adapted to maintain proper printer waste liner spool operations when the liner is wound after application of the label.
-
公开(公告)号：US20230234917A1
公开(公告)日：2023-07-27
申请号：US18001238
申请日：2021-06-09
发明人： Spencer Cory PECK , Jenny LIU , Timothy F. BRIGGS , John Robert PROUDFOOT , William MCELROY , Robert Walter MYERS , Steven John TAYLOR
IPC分类号： C07C237/10 , A61P35/00 , C07K5/062 , C07D305/08 , C07C275/14 , C07C271/20 , C07F9/40 , C07F9/42 , C07C317/08 , C07F5/02 , C07C237/22 , C07D263/32 , C07D233/64 , C07D257/04 , C07D249/08 , C07D271/06 , C07D271/10 , C07D249/04 , C07C255/29 , C07D213/40 , C07D333/20 , C07D235/16
CPC分类号： C07C237/10 , A61P35/00 , C07K5/06026 , C07D305/08 , C07C275/14 , C07C271/20 , C07F9/4006 , C07F9/425 , C07C317/08 , C07F5/027 , C07C237/22 , C07D263/32 , C07D233/64 , C07D257/04 , C07D249/08 , C07D271/06 , C07D271/10 , C07D249/04 , C07C255/29 , C07D213/40 , C07D333/20 , C07D235/16 , C07C2601/14
摘要： The present disclosure relates to compounds of formulas (A) and (I), pharmaceutically acceptable salts thereof, and solvates of any of the foregoing, pharmaceutical compositions comprising the same, methods of preparing the same, intermediate compounds useful for preparing the same, and methods for treating or prophylaxis of diseases, in particular cancer, such as colorectal cancer, using the same.
-
公开(公告)号：US20230134776A1
公开(公告)日：2023-05-04
申请号：US17626519
申请日：2020-07-10
IPC分类号： C07C311/29 , C07D295/26 , C07C311/51 , C07C317/22 , C07C69/16 , C07D213/71 , C07C309/42 , C07D307/64 , C07D233/84 , C07D305/08 , C07D207/404 , C07D211/54 , C07D239/38 , C07D205/06 , C07D205/12 , C07D487/10 , C07D249/08 , C07D249/10 , C07D235/16 , C07D277/30 , C07D263/32
摘要： This disclosure relates to cannabinoid derivatives having the structure of formula (I), pharmaceutical compositions comprising them, and methods of using the cannabinoid derivatives in treating or preventing a diseases associated with a cannabinoid receptor in subject in need thereof, wherein the cannabinoid receptor is one or more of CB1, CB2, 5HT1A, 5HT2A, GPR18, GPR55, GPR119, TRPV1, TRPV2, PPARγ or a μ-opioid receptor.
-
公开(公告)号：US11530180B2
公开(公告)日：2022-12-20
申请号：US17117004
申请日：2020-12-09
IPC分类号： C07C279/18 , C07C279/28 , C07C317/14 , C07D239/14 , C07D265/08 , C07D265/16 , C07D265/36 , C07D295/155 , C07D311/68 , C07D401/12 , C07D403/12 , C07D413/12 , C07D417/12 , C07D471/04 , A61K31/337 , A61K31/704 , C07D235/16 , C07D213/74 , C07D233/88 , C07D215/42 , C07D279/06
摘要： The disclosure provides, inter alia, alpha-5 beta-1 inhibitors, pharmaceutical compositions comprising alpha-5 beta-1 inhibitors, methods for treating diseases using alpha-5 beta-1 inhibitors, and processes for making alpha-5 beta-1 inhibitors.
-
公开(公告)号：US20220340548A1
公开(公告)日：2022-10-27
申请号：US17614854
申请日：2020-05-25
申请人： Galapagos NV
发明人： Luke Jonathan ALVEY , Denis BUCHER , Nicolas DESROY , Hélène Marie JARY , Christophe PEIXOTO , Taoues TEMAL-LAÏB , Amynata TIRERA , Florence Marie-Emilie BONNATERRE , Béranger DUTHION
IPC分类号： C07D405/10 , C07D401/10 , C07D235/16 , C07D471/04 , C07D519/00 , A61P1/00 , A61P19/02 , A61P9/00 , A61P11/00 , A61P37/00
摘要： The present invention discloses compounds according to Formula I: wherein R1a, R1b, R1c, R2a, W1, W2, X1, X2, X3, Y, and Z are as defined herein.
The present invention relates to compounds, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of inflammatory diseases, autoinflammatory diseases, autoimmune diseases, proliferative diseases, fibrotic diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformation, diseases involving impairment of bone turnover, diseases associated with hypersecretion of IL-6, diseases associated with hypersecretion of TNFα, interferons, IL-12 and/or IL-23, respiratory diseases, endocrine and/or metabolic diseases, cardiovascular diseases, dermatological diseases, and/or abnormal angiogenesis associated diseases by administering the compound of the invention.-
公开(公告)号：US20220233475A1
公开(公告)日：2022-07-28
申请号：US17667323
申请日：2022-02-08
IPC分类号： A61K31/137 , A61K45/06 , A61K31/198 , A61K31/4045 , A61K31/428 , A61K31/473 , A61K31/48 , A61K31/506 , A61K31/519 , A61K31/5513 , A61K31/4184 , C07C211/29 , C07C215/08 , C07C215/54 , C07C217/62 , C07D209/14 , C07D235/16 , C07D471/04
摘要： The present invention provides a method of inhibiting, suppressing or preventing levodopa-induced dyskinesia in a patient suffering from Parkinson's Disease, comprising the step of administering to the patient a pharmaceutical composition comprising at least one compound of the invention. The present invention further provides a method of inhibiting, suppressing or preventing Parkinson's Disease in a patient, comprising the step of administering to the patient a pharmaceutical composition comprising at least one compound of the invention.
-
公开(公告)号：US20220135574A1
公开(公告)日：2022-05-05
申请号：US17577139
申请日：2022-01-17
申请人： LG CHEM, LTD.
发明人： Young Kwan Kim , Sang Yun Park , Hyun Woo Joo , Eun Sil Choi , Seung Yup Paek , Seung Wan Kang , Byung Gyu Kim , Chang Seok Lee , Sung Wook Kim , Sang Dae Lee
IPC分类号： C07D487/04 , C07D401/04 , A61K31/4725 , C07C59/31 , C07C229/42 , C07C229/44 , C07C317/22 , C07D207/06 , C07D209/08 , C07D211/34 , C07D213/30 , C07D213/64 , C07D213/70 , C07D231/56 , C07D235/16 , C07D239/34 , C07D241/18 , C07D261/08 , C07D277/34 , C07D307/42 , C07D307/80 , C07D311/58 , C07D317/46 , C07D317/72 , C07D333/16 , C07D401/10 , C07D401/12 , C07D401/14 , C07D405/04 , C07D405/12 , C07D405/14 , C07D407/04 , C07D409/04 , C07D409/10 , C07D409/14 , C07D413/10 , C07D413/12 , C07D417/10
摘要： The present invention relates to a biaryl derivative expressed by the chemical formula 1, a method for producing the biaryl derivative, a pharmaceutical composition comprising same, and use of same, the biaryl derivative expressed by the chemical formula 1, as a GPR120 agonist, promoting GLP-1 generation in the gastro-intestinal tract, reducing insulin resistance in the liver, muscles and the like from anti-inflammatory activity in the macrophage, pancreatic cells and the like, and allowing effective use in prevention or treatment of inflammation or metabolic diseases such as diabetes, complications from diabetes, obesity, non-alcoholic fatty liver disease, fatty liver disease, and osteoporosis.
-
公开(公告)号：US11261186B2
公开(公告)日：2022-03-01
申请号：US15539310
申请日：2015-12-23
申请人： LG CHEM, LTD.
发明人： Young Kwan Kim , Sang Yun Park , Hyun Woo Joo , Eun Sil Choi , Seung Yup Paek , Seung Wan Kang , Byung Gyu Kim , Chang Seok Lee , Sung Wook Kim , Sang Dae Lee
IPC分类号： C07D239/34 , C07D401/10 , C07D403/10 , C07D471/04 , C07D487/04 , C07D401/04 , A61K31/4725 , C07C59/31 , C07C229/42 , C07C229/44 , C07C317/22 , C07D207/06 , C07D209/08 , C07D211/34 , C07D213/30 , C07D213/64 , C07D213/70 , C07D231/56 , C07D235/16 , C07D241/18 , C07D261/08 , C07D277/34 , C07D307/42 , C07D307/80 , C07D311/58 , C07D317/46 , C07D317/72 , C07D333/16 , C07D401/12 , C07D401/14 , C07D405/04 , C07D405/12 , C07D405/14 , C07D407/04 , C07D409/04 , C07D409/10 , C07D409/14 , C07D413/10 , C07D413/12 , C07D417/10
摘要： Compounds having the chemical formula 1, a method for producing the compounds of chemical formula 1, a pharmaceutical composition comprising same, and use thereof as a GPR120 agonist for prevention or treatment of inflammation or metabolic diseases such as diabetes, complications from diabetes, obesity, non-alcoholic fatty liver disease, fatty liver disease, and osteoporosis.
-
公开(公告)号：US20190194143A1
公开(公告)日：2019-06-27
申请号：US16323508
申请日：2017-08-15
发明人： Lin Zhi , Matthew P. Grote , Raja K. Reddy , Wenyu Li , William Craigo
IPC分类号： C07D235/16 , C07D233/61 , C07D405/10 , C07D209/18 , C07D231/12 , C07D213/81 , C07D409/06 , C07D333/38 , C07D409/12 , A61P3/10
CPC分类号： C07D235/16 , A61P3/10 , C07D209/18 , C07D213/81 , C07D231/12 , C07D233/61 , C07D333/38 , C07D405/10 , C07D407/10 , C07D409/06 , C07D409/12
摘要： Provided herein are compounds, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or co-crystals and prodrugs thereof which have glucagon receptor antagonist or inverse agonist activity. Further, provided herein are pharmaceutical compositions and methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance and hyperglycemia.
-
公开(公告)号：US09913827B2
公开(公告)日：2018-03-13
申请号：US15456439
申请日：2017-03-10
申请人： IGNYTA, INC.
发明人： Roger P. Bakale , Peter D. Brown , Jian Chen , Anthony S. Drager , Rachel Y. LaBell , Robert E. McKean , Piyush R. Patel , Renee C. Roemmele
IPC分类号： A61K31/4184 , C07D235/16 , A61K47/42 , A61K9/14
CPC分类号： A61K31/4184 , A61K9/14 , A61K47/42 , C07D235/16
摘要： The present invention is directed to bendamustine esters and bendamustine amides and their use for the treatment of cancer.
-
-
-
-
-
-
-
-
-
搜索结果
405 条记录 (耗时 0.026 秒)
